Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

NCT02900976 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02900976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02900976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2017
Completion date
December 31, 2025
Enrollment
18 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

ebv-related post-transplant lymphoproliferative disorder, monomorphic post-transplant lymphoproliferative disorder, polymorphic post-transplant lymphoproliferative disorder, recurrent monomorphic post-transplant lymphoproliferative disorder, recurrent polymorphic post-transplant lymphoproliferative disorder, refractory monomorphic post-transplant lymphoproliferative disorder, refractory polymorphic post-transplant lymphoproliferative disorder